InvestorsHub Logo
Followers 827
Posts 119550
Boards Moderated 15
Alias Born 09/05/2002

Re: jbog post# 16203

Tuesday, 11/29/2016 1:54:10 PM

Tuesday, November 29, 2016 1:54:10 PM

Post# of 20689
MNTA has designed around ABBV's Humira-formulation patents, according to CW. So, with ABBV's US composition-of-matter patent on Humira soon to expire, ABBV's protection from FoB competition in the US market would seem to boil down to its various "method of use" (i.e. indication-specific) patents.

Please see #msg-118781959 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”